glp-1 cardiovascular outcomes trial august 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Researchers issue a warning Gymnema Bundle:1 month supply

glp-1 cardiovascular outcomes trial august 2025 In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Researchers issue a warning Gymnema Bundle:1 month supply

Researchers issue a warning that GLP-1RAs may be dangerous for children

Diarrhea affects a smaller percentage but can emerge as the body adjusts, sometimes alternating with constipation during the first 4–6 weeks of therapy

Gymnema

Bundle:1 month supply

Addressing modifiable risk factors reduces the likelihood of recurrent episodes regardless of the initial trigger